摘要
目的研究低密度脂蛋白受体相关蛋白4(LRP4)在甲状腺乳头状癌(PTC)中的表达和意义。方法挖掘Oncomine数据库中关于LRP4的信息,并对目前数据库中资料进行二次分析,探索其在PTC中的表达及意义。结果Oncomine数据库中共收集了400项不同肿瘤中关于LRP4的研究,与正常组织相比,LRP4表达明显增高的有11项,表达明显降低的有7项。共3项研究中的5个数据集包含135例样本涉及LRP4在PTC组织与正常组织中的表达,对这5项研究结果进行Meta分析显示,LRP4在所有差异表达基因中的中位数值排名为11,P=3.06×10^(-8),提示LRP4在PTC中高表达。LRP4在PTC组织中的表达量均明显高于正常组织,差异均有统计学意义(P﹤0.01)。LRP4高表达与低表达患者的生存情况比较,差异无统计学意义(P﹥0.05)。结论通过对Oncomine基因芯片数据库中肿瘤相关基因信息的深入挖掘显示,LRP4在PTC组织中高表达,提示LRP4可能是PTC的致癌基因,为PTC的靶向治疗提供了方向。研究未发现LRP4的高低表达与PTC患者的生存有关。
Objective To study the expression of low-density lipoprotein receptor related protein 4(LRP4)in papil-lary thyroid carcinoma(PTC)and its clinical significance.Method The expression information about LRP4 in the Onco-mine database was mined,and the data in the current database was re-analyzed to explore its expression and clinical sig-nificance in PTC.Result A total of 400 serials on LRP4 in different tumors have been collected in the Oncomine data-base.Among all studies,11 have significantly higher expression of LRP4,and 7 have significantly lower expression com-pared with those in normal tissues.A total of 5 data sets in 3 studies contained 135 samples involving the expression of LRP4 in PTC tissues and normal tissues.Meta-analysis of these five studies showed that the median value of LRP4 among all differentially expressed genes ranked as 11,P=3.06×10^(-8),suggesting that LRP4 was up-regulated in PTC.The expression of LRP4 in PTC tissues was significantly higher than that in normal tissues,and the differences was statistical-ly significant(P<0.01).There was no statistically significant difference in the overall survival of patients with high and low expression of LRP4(P>0.05).Conclusion By in-depth mining of cancer-related gene information in the Oncomine gene express array database,LRP4 is up-regulated in the PTC tissue.This finding suggests that LRP4 may be the onco-gene of PTC,which provides a potential target for PTC treatment.Besides,the study did not find that the expression of LRP4 is related to the survival of PTC patients.
作者
冯鑫源
田昀灵
傅松波
邴志桐
赵楠
洪成恩
王素媛
龚文倩
吴啸天
FENG Xinyuan;TIAN Yunling;FU Songbo;BING Zhitong;ZHAO Nan;HONG Cheng’en;WANG Suyuan;GONG Wenqian;WU Xiaotian(the First School of Clinical Medical,Lanzhou University,Lanzhou 730000,Gansu,China;Department of Endocrinology,the First Hospital of Lanzhou University,Lanzhou 730000,Gansu,China;Institute of Modern Physics,Chinese Academy of Sciences,Lanzhou 730000,Gansu,China)
出处
《癌症进展》
2021年第14期1425-1428,共4页
Oncology Progress
基金
甘肃省自然科学基金(21JR1RA066)
甘肃省科技计划项目(20JR10FA667)
兰州大学学生创新创业行动计划项目(20200060087)。
